HOME > News > Announcements > 2023.12.15 Glac Biotech’s PRONULIFE® LvUCare Wins Top Innovation Award from the Lactic Acid Bacteria Association
2023.12.15 Glac Biotech’s PRONULIFE® LvUCare Wins Top Innovation Award from the Lactic Acid Bacteria Association
Innovation in probiotics often starts with a simple question: how can we solve the health challenges of modern life? For Glac Biotech, that question led to the creation of PRONULIFE® LvUCare — a functional probiotic designed to support liver health. And in 2023, the product’s breakthrough impact was officially recognized, earning the Top Innovation Award from the Lactic Acid Bacteria Association.
A Solution for Modern Lifestyles
Late nights, endless work, social drinking, and constant stress — these are realities for many in today’s fast-paced world. Over time, such habits take a toll on metabolism, often leading to conditions like metabolic syndrome and hyperuricemia (high uric acid levels). Taiwan, in fact, has the highest global incidence of gout, and cases are increasingly affecting younger people.
Recognizing the urgent need for a solution, Glac’s research team developed LvUCare, a probiotic raw material specifically tailored for people at risk of liver strain and metabolic imbalance.
The Science of the Gut–Liver Axis
The science behind LvUCare lies in the gut–liver axis theory, which shows how gut microbiota not only regulate metabolism but also influence the absorption of toxins into circulation. Poor microbial balance puts the liver under direct stress.
By targeting this axis, LvUCare works from the inside out — rebalancing gut ecology, improving metabolic conditions, and helping preserve healthy liver function. The result is a probiotic solution that brings measurable, positive effects to overall health.
PRONULIFE®: A Mark of Quality and Functionality
LvUCare is part of Glac Biotech’s PRONULIFE® series, a line of exclusive functional probiotic powders created under stringent criteria:
Looking Ahead: Building a Healthier Future
As science and medicine advance, the world increasingly demands targeted, functional probiotic solutions. Glac Biotech continues to invest heavily in research, innovation, and quality control, creating specialized probiotics for different populations while building a fully integrated, vertically aligned supply chain.
Winning the Lactic Acid Bacteria Association’s Top Innovation Award is not just a recognition of Glac Biotech’s R&D excellence — it is proof of its deep understanding of global health trends. Looking forward, Glac is committed to launching even more innovative probiotics to enhance wellness and bring lasting benefits to people worldwide.
A Solution for Modern Lifestyles
Late nights, endless work, social drinking, and constant stress — these are realities for many in today’s fast-paced world. Over time, such habits take a toll on metabolism, often leading to conditions like metabolic syndrome and hyperuricemia (high uric acid levels). Taiwan, in fact, has the highest global incidence of gout, and cases are increasingly affecting younger people.
Recognizing the urgent need for a solution, Glac’s research team developed LvUCare, a probiotic raw material specifically tailored for people at risk of liver strain and metabolic imbalance.
The Science of the Gut–Liver Axis
The science behind LvUCare lies in the gut–liver axis theory, which shows how gut microbiota not only regulate metabolism but also influence the absorption of toxins into circulation. Poor microbial balance puts the liver under direct stress.
By targeting this axis, LvUCare works from the inside out — rebalancing gut ecology, improving metabolic conditions, and helping preserve healthy liver function. The result is a probiotic solution that brings measurable, positive effects to overall health.
PRONULIFE®: A Mark of Quality and Functionality
LvUCare is part of Glac Biotech’s PRONULIFE® series, a line of exclusive functional probiotic powders created under stringent criteria:
- Strains sourced from high-quality origins.
- Proven combinations with clinical efficacy.
- Supported by global patents and SCI journal publications.
- Validated through human trials and functional testing.
Looking Ahead: Building a Healthier Future
As science and medicine advance, the world increasingly demands targeted, functional probiotic solutions. Glac Biotech continues to invest heavily in research, innovation, and quality control, creating specialized probiotics for different populations while building a fully integrated, vertically aligned supply chain.
Winning the Lactic Acid Bacteria Association’s Top Innovation Award is not just a recognition of Glac Biotech’s R&D excellence — it is proof of its deep understanding of global health trends. Looking forward, Glac is committed to launching even more innovative probiotics to enhance wellness and bring lasting benefits to people worldwide.
-
2024.3.29 Glac Biotech’s Totipro® PE0301 Wins NutraIngredients Award, Reinforcing Global Leadership in Postbiotics
-
2023.3.23 Glac Biotech’s Flagship Probiotic CP-9 Reaches New Heights With Breakthrough Patent in Neonatal Jaundice Resea
-
Totipro® PE0401, the Postbiotic That Brings Health Within Reach — Making Daily Nutrition Simple and Joyful